期刊
MULTIPLE SCLEROSIS JOURNAL
卷 23, 期 3, 页码 378-381出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458516676899
关键词
Factors; treatment response; surrogate outcomes
资金
- Merck Serono
- Teva
- Novartis
- Roche
- Genzyme
- Biogen
Multiple sclerosis is a highly heterogeneous disease; the quantitative assessment of disease progression is problematic for many reasons, including the lack of objective methods to measure disability and the long follow-up times needed to detect relevant and stable changes. For these reasons, the importance of prognostic markers, markers of response to treatments and of surrogate endpoints, is crucial in multiple sclerosis research. Aim of this report is to clarify some basic definitions and methodological issues about baseline factors to be considered prognostic markers or markers of response to treatment; to define the dynamic role that variables must have to be considered surrogate markers in relation to specific treatments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据